Recruiting PHASE1 INTERVENTIONAL 1-arm NCT06786234

A Phase 1 Study to Assess STP938 as a Monotherapy in Adults With High Risk Essential Thrombocythaemia

An Open-Label, Phase 1b Study to Evaluate Safety, Tolerability & Preliminary Activity of the CTPS1 Inhibitor STP938 in Adult Subjects With High Risk Essential Thrombocythaemia Who Are Resistant to or Intolerant of Hydroxycarbamide Therapy

Sponsor: Step Pharma, SAS

Conditions Essential Thrombocythaemia

Interventions STP938

Updated 4 times since 2025 Last updated: Jan 27, 2026 Started: Jun 18, 2025 Primary completion: May 31, 2026 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Essential Thrombocythaemia and is currently actively recruiting participants. Step Pharma, SAS leads this study, which shows 4 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE1
Aug 2025 — Feb 2026 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
May 2025 — Aug 2025 [monthly]

Not Yet Recruiting PHASE1
Feb 2025 — May 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Step Pharma, SAS

Data source: Step Pharma, SAS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Brest, France , Cardiff, United Kingdom , London, United Kingdom , Marseille, France , Nantes, France , Nice, France , Nîmes, France , Oxford, United Kingdom , Paris, France , Sheffield, United Kingdom and 2 more locations